Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC ESI-09 | 263707-16-0 | 99.15% | 330.77 | 100 MG
Supplier: Medchemexpress LLC HY16704100MG
ESI-09 is a novel noncyclic nucleotide EPAC antagonist that inhibits EPAC1 and EPAC2 activity, with IC50 values of 3.2 μM for EPAC1 and 1.4 μM for EPAC2. It exhibits increased potency in competing with 8-NBD-cAMP binding and inhibits cAMP-mediated GEF activity. ESI-09 has been shown to inhibit Akt phosphorylation and the migration of pancreatic cancer cells. It also suppresses EPAC1-mediated adhesion of PDA cells on collagen I and reduces bacterial counts in HUVECs infected with *R. australis*, protecting against infection in vivo.
- Novel noncyclic nucleotide EPAC antagonist
- Inhibits EPAC1 and EPAC2 activity
- Increased potency in 8-NBD-cAMP binding competition
- Inhibits cAMP-mediated EPAC2 and EPAC1 GEF activity
- Inhibits Akt phosphorylation
- Suppresses pancreatic cancer cell migration
- Reduces bacterial counts post-infection with *R. australis*
- Protects against *R. australis* infection in vivo
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?